Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ONO-6950 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Experimental 200 mg dose | EXPERIMENTAL | - |
| Active Comparator | ACTIVE_COMPARATOR | - |
| Placebo Comparator | PLACEBO_COMPARATOR | - |
| E | EXPERIMENTAL | ONO-6950 |
| P | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ONO-6950 | DRUG | 200 mg QD for 8 days |
| Placebo | DRUG | Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner |
| Montelukast | DRUG | 10 mg Montelukast QD for 8 days |
Inclusion Criteria: * Patients of both genders, between 18 to 60 years of age, with bronchial asthma symptoms for at least 6 months * Patients with FEV1 ≥ 70% of predicted after withholding short-acting β agonists for at least 8 hours prior to testing * Screening allergen challenge demonstrates tha...
ONO-6950 is an investigational small molecule being studied for the treatment of asthma. It has also been evaluated in healthy adult subjects to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is in clinical development and is not yet approved by regulatory authorities.
ONO-6950 is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker BWAY. The drug is in Phase 2 clinical development for asthma and has completed a Phase 1 study in healthy volunteers.
ONO-6950 is in Phase 2 clinical development for asthma. It has completed a Phase 1 study in healthy adult subjects and a Phase 2 study in patients with asthma. The drug is investigational and has not been approved by the FDA or other regulatory agencies.
ONO-6950 has been studied in two completed clinical trials. NCT01405651 was a Phase 1 study in healthy adult subjects in the United States with 24 participants. NCT01551147 was a Phase 2 placebo and active controlled study following allergen challenge in asthma patients in Canada with 25 participants.
ONO-6950 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is a small molecule being developed by BrainsWay Ltd. for the treatment of asthma.